Exact Sciences Corporation
EXAS
Pozycja w akcjach
#1154
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Cena akcji
$104.91
Ostatnia synchronizacja: 2026-03-23
Kapitalizacja rynkowa
$20.03B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
71.34%
Kraj
US
Handel Exact Sciences Corporation (EXAS)
Kategoria
Healthcare
EPS dla Exact Sciences Corporation (EXAS)
EPS na dzień December 2025 TTM: $-1.10
Według najnowszych raportów finansowych i ceny akcji firmy Exact Sciences Corporation, obecny EPS (TTM) wynosi $-1.10. Na koniec roku 2024 firma miała EPS w wysokości $-5.59, wzrost w porównaniu do do EPS z roku 2023, który wynosił $-1.13.
Historia EPS dla Exact Sciences Corporation od 2000 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-1.10 | 0.00% |
| 2025 | $-1.10 | -80.32% |
| 2024 | $-5.59 | 394.69% |
| 2023 | $-1.13 | -68.08% |
| 2022 | $-3.54 | 1.72% |
| 2021 | $-3.48 | -36.15% |
| 2020 | $-5.45 | 236.42% |
| 2019 | $-1.62 | 13.29% |
| 2018 | $-1.43 | 44.44% |
| 2017 | $-0.99 | -39.26% |
| 2016 | $-1.63 | -4.68% |
| 2015 | $-1.71 | 36.80% |
| 2014 | $-1.25 | 81.16% |
| 2013 | $-0.69 | -21.59% |
| 2012 | $-0.88 | 60.00% |
| 2011 | $-0.55 | 96.43% |
| 2010 | $-0.28 | 0.00% |
| 2009 | $-0.28 | -22.22% |
| 2008 | $-0.36 | -18.18% |
| 2007 | $-0.44 | -10.20% |
| 2006 | $-0.49 | -10.91% |
| 2005 | $-0.55 | -24.66% |
| 2004 | $-0.73 | -51.33% |
| 2003 | $-1.50 | -7.41% |
| 2002 | $-1.62 | 14.08% |
| 2001 | $-1.42 | -82.53% |
| 2000 | $-8.13 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $18.62 | -1,792.73% |
US
|
|
| $5.65 | -613.64% |
US
|
|
| $-1.36 | 23.64% |
US
|
|
| - | - |
CN
|
|
| $5.09 | -562.73% |
US
|
